{"product_id":"infusystem-pestle-analysis","title":"InfuSystem PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our focused PESTLE analysis of InfuSystem—revealing political, economic, social, technological, legal, and environmental forces shaping its growth. Ideal for investors and strategists, this concise report highlights regulatory risks, reimbursement trends, and tech opportunities you can't ignore. Purchase the full version for the complete, actionable roadmap and downloadable templates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChanges in federal and state healthcare agendas can expand or constrain infusion therapy coverage, with Medicare covering roughly 65 million beneficiaries (2024) driving payer mix. The Enhancing Oncology Model (EOM) launched in 2023 shifts incentives toward value-based ambulatory pump use. Policy stability supports capital planning, while abrupt shifts raise demand volatility; active monitoring enables timely contract and pricing adjustments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic payer reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare and Medicaid reimbursement rules materially affect INFU revenue from rentals, service, and supplies, with CMS competitive bidding historically cutting device rates by as much as 50% in affected categories and posing margin risk to pump programs. Coding, coverage, and payment updates (annual HCPCS\/fee-schedule changes) can quickly shift pump profitability and utilization. Favorable payer rulings or expanded coverage can unlock volume while proactive advocacy and payer education help preserve access and stabilize reimbursement. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment procurement channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeterans Health Administration and other federal facilities, which serve roughly 9 million enrolled veterans across more than 1,200 sites, are major buyers of infusion and biomedical services. Contract awards hinge on compliance, competitive pricing and performance metrics; many contracts are multi-year (commonly 3–5 years) providing visibility but demanding strict SLAs. Timing of awards is sensitive to annual federal budget cycles and continuing resolutions, causing procurement delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade and tariff exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTariffs on China-origin medical components and devices can be as high as 25% under US Section 301 measures, raising InfuSystem's equipment and parts costs and compressing margins. Diversifying suppliers across Mexico, Vietnam and EU partners cuts single-country exposure and shortens lead times. Alignment with US\/EU regulatory pathways such as MDR speeds approvals and customs clearance; geopolitical tensions force larger inventory buffers, increasing working capital needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariff risk: up to 25% on China-origin goods\u003c\/li\u003e\n\u003cli\u003eSourcing: Mexico, Vietnam, EU reduce shock exposure\u003c\/li\u003e\n\u003cli\u003eRegulatory: US\/EU alignment accelerates approvals\u003c\/li\u003e\n\u003cli\u003eWorking capital: higher inventory buffers raise cash needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePreparedness spending and cancer care initiatives drive InfuSystem equipment refreshes and service demand; CDC PHEP funding was $675 million in FY2024 and NCI’s FY2024 budget exceeded $7.5 billion, supporting oncology device upgrades. Shifts to home- and community-based care—Medicare home health spending ~ $19 billion in 2023—reshape delivery models and increase offsite infusion needs. Grants and subsidies catalyze technology upgrades, while budget reprioritization can delay orders in low-growth years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreparedness funding: CDC PHEP $675M (FY2024)\u003c\/li\u003e\n\u003cli\u003eCancer care funding: NCI \u0026gt; $7.5B (FY2024)\u003c\/li\u003e\n\u003cli\u003eHome care trend: Medicare home health ≈ $19B (2023)\u003c\/li\u003e\n\u003cli\u003eRisk: budget reprioritization → delayed orders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy-driven infusion shifts: Medicare, VHA contracts, tariffs and reimbursement risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal\/state healthcare policy and Medicare (≈65M beneficiaries in 2024) heavily shape payer mix and infusion coverage; EOM and value-based oncology models (since 2023) shift incentives toward ambulatory pumps. Reimbursement and CMS bidding (historically up to 50% rate cuts in categories) drive margin risk; VHA (≈9M enrollees, ~1,200 sites) provides multi-year contract visibility. Tariffs (up to 25% on China-origin goods) and FY2024 preparedness\/NCI budgets affect costs and demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare beneficiaries (2024)\u003c\/td\u003e\n\u003ctd\u003e≈65M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVHA enrollees\/sites\u003c\/td\u003e\n\u003ctd\u003e≈9M \/ ~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff risk\u003c\/td\u003e\n\u003ctd\u003eUp to 25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDC PHEP (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$675M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI budget (FY2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$7.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect InfuSystem across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and region-specific regulatory context. Designed for executives and investors, it delivers forward-looking insights to identify risks, opportunities, and strategic actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondensed InfuSystem PESTLE that’s visually segmented by category for quick meeting reference, easily editable with simple language and shareable format to align teams and support risk discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement and payer mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInfuSystem’s pricing power and margins are sensitive to commercial vs public payer mix; with public payers (Medicare\/Medicaid) roughly ~45% of payments in the sector, a heavier public mix can compress reimbursed rates.\u003c\/p\u003e\n\u003cp\u003eDenial rates and prior authorization friction — commonly in the 5–12% denial range in 2024 for outpatient device claims — lengthen cash conversion cycles, often 60–90 days for durable medical equipment providers.\u003c\/p\u003e\n\u003cp\u003eBundled payment initiatives trend to compress device-plus-service economics, reducing per-patient device margin; proactive revenue-cycle management (denial reduction, automated prior auth) is critical to sustain liquidity and working capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and input costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrice inflation in disposables, batteries and parts—driven by supply-chain pressures and a US CPI of 3.4% in 2024 (BLS)—squeezes InfuSystem gross margins as input costs rise. Wage inflation for biomedical equipment technicians (median ~$56,000–$58,000 annually in recent BLS data) increases field-service expense. Index-linked contracts and surcharges limit margin erosion, while lean inventory and vendor consolidation boost bargaining power and lower purchase price volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and capital intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher rates elevate borrowing costs for fleet expansion and depot facilities, with US federal funds near 5.25–5.50% in mid‑2025 driving wider spreads on ABL and term loans. Payback periods on pumps and tooling must clear higher hurdle rates, extending payback multiples. Leasing strategies can preserve cash while meeting demand. Rate declines would unlock accretive refresh cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProvider consolidation and GPOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProvider mergers concentrate purchasing via GPOs; Vizient, Premier and HealthTrust together account for roughly 60% of U.S. hospital purchasing spend, intensifying price pressure. Larger customers demand sharper pricing and broader SLAs while vendors gain volume visibility and lower churn, enabling InfuSystem to negotiate multi-year placements. Differentiated service levels and uptime guarantees defend margin during aggressive bid cycles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConcentration: top GPOs ≈60% of hospital spend\u003c\/li\u003e\n\u003cli\u003eBuyer power: sharper pricing + broader SLAs demanded\u003c\/li\u003e\n\u003cli\u003eVendor benefits: volume visibility, lower churn\u003c\/li\u003e\n\u003cli\u003eMargin defense: differentiated service levels in bids\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand resilience in oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCancer incidence remains high—American Cancer Society estimated about 1.96 million new US cancer cases in 2024—supporting steady oncology infusion demand and ongoing multi-cycle therapy regimens that drive utilization.\u003c\/p\u003e\n\u003cp\u003eMedically necessary infusions show resilience in downturns, with procedure deferrals lower than elective care, though regional swings in orders and staffing create timing volatility for InfuSystem revenues and scheduling.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 US new cases ≈ 1.96M (ACS)\u003c\/li\u003e\n\u003cli\u003eOncology infusions: ongoing multi-cycle demand\u003c\/li\u003e\n\u003cli\u003eMacroeconomic impact: modest vs elective procedures\u003c\/li\u003e\n\u003cli\u003eRegional variability affects order timing and staffing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy-driven infusion shifts: Medicare, VHA contracts, tariffs and reimbursement risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInfuSystem faces margin pressure from a ~45% public-payer mix, 5–12% denial rates lengthening cash cycles to 60–90 days, and 2024 CPI-driven input inflation (~3.4%) plus wage pressures for technicians (~$56–58k). Higher rates (fed funds ~5.25–5.50% mid‑2025) raise financing costs; GPO consolidation (~60% hospital spend) intensifies price pressure while 2024 cancer incidence (~1.96M) supports steady oncology demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic payer share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDenial rate\u003c\/td\u003e\n\u003ctd\u003e5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CPI 2024\u003c\/td\u003e\n\u003ctd\u003e3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds mid‑2025\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS cancer cases 2024\u003c\/td\u003e\n\u003ctd\u003e~1.96M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO concentration\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eInfuSystem PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact, fully formatted InfuSystem PESTLE Analysis you’ll receive after purchase—professionally structured and ready to use. No placeholders or teasers: this screenshot reflects the real file delivered instantly upon payment. The layout, content, and depth of analysis visible here are exactly what you’ll download after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162665595257,"sku":"infusystem-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/infusystem-pestle-analysis.png?v=1762706053","url":"https:\/\/portersfiveforce.com\/products\/infusystem-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}